# R21 Roche: 3-Way Tau Tracers in AD

> **NCT05464368** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 38 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** [18F]RO-948
- **DRUG:** 18F-MK6240
- **DRUG:** 18F-GTP1

## Key facts

- **NCT ID:** NCT05464368
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05464368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05464368, "R21 Roche: 3-Way Tau Tracers in AD". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05464368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*